AMRI Announces Increased Production of Hydroxychloroquine Sulfate for COVID-19 Treatment
FDA approved hydroxychloroquine sulfate for emergency use as a treatment for some hospitalized patients with COVID-19.
AMRI, a contract research development and manufacturing organization, announced on April 30, 2020 that it will be increasing its production of hydroxychloroquine sulfate (HCQ) API at its Rensselaer, NY, manufacturing facility to assist in the fight against COVID-19.
According to a company press release, FDA approved HCQ for emergency use as a treatment for some hospitalized patients with COVID-19.
“We look forward to working with our drug product producers, government agencies, and associated health authorities globally to ensure access to this API, as needed,” said the company in the press release.
Source: AMRI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
